Central nervous system dysfunction as the first manifestation of multiple organ dysfunction syndrome in stem cell transplant patients

B. Gordon, E. Lyden, J. Lynch, S. Tarantolo, Z. S. Pavletic, M. Bishop, E. Reed, A. Kessinger, W. Haire

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Development of CNS dysfunction in the setting of hematopoietic stem cell transplant (HSCT) has been previously shown to predict for subsequent second organ dysfunction and death. In this paper, we describe the characteristics of this isolated CNS dysfunction, and its relationship to multiple organ dysfunction syndrome (MODS) after HSCT. Twenty-one of 186 patients undergoing HSCT developed CNS dysfunction as their first organ dysfunction a mean of 22.8 ± 0.9 days after the start of the preparative regimen. Compared with 137 patients who developed no organ dysfunction, patients presenting with CNS dysfunction were more likely to have undergone allogeneic HSCT (P = 0.001) and to have received a total body irradiation-based regimen (P = 0.001), and were less likely to have been transplanted for lymphoma (P = 0.008). Patients who developed CNS dysfunction were more likely to die than those with no organ dysfunction (P < 0.001). Of the 21 patients who developed CNS dysfunction, 48% resolved their dysfunction by a mean of 4.6 days later without progression to second organ dysfunction, and 90% of these patients survived to day 100. Fifty-two percent of patients with CNS dysfunction progressed to second organ dysfunction (pulmonary or hepatic) a mean of 5.5 days later, and only 36% survived to day 100 (P = 0.02). The patients who progressed to second organ dysfunction and those who did not were not different in terms of type of HSCT (allogeneic vs autologous), stem cell source (blood vs bone marrow), age, diagnosis or preparative regimen. Development of CNS dysfunction in the setting of HSCT, as with other organ dysfunctions (such as hepatic veno-occlusive disease), probably represents an early manifestation of a systemic disorder predisposing for MODS, increasing the risk of transplant-related mortality. Early systemic therapies directed at modulating this systemic disorder are probably indicated.

Original languageEnglish (US)
Pages (from-to)79-83
Number of pages5
JournalBone marrow transplantation
Volume25
Issue number1
DOIs
StatePublished - Jan 1 2000

Fingerprint

Multiple Organ Failure
Stem Cells
Central Nervous System
Hematopoietic Stem Cells
Transplants
Hepatic Veno-Occlusive Disease
Whole-Body Irradiation
Secondary Prevention
Lymphoma
Bone Marrow
Lung
Mortality
Liver

Keywords

  • CNS dysfunction
  • Multiple organ dysfunction
  • Stem cell transplant

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Central nervous system dysfunction as the first manifestation of multiple organ dysfunction syndrome in stem cell transplant patients. / Gordon, B.; Lyden, E.; Lynch, J.; Tarantolo, S.; Pavletic, Z. S.; Bishop, M.; Reed, E.; Kessinger, A.; Haire, W.

In: Bone marrow transplantation, Vol. 25, No. 1, 01.01.2000, p. 79-83.

Research output: Contribution to journalArticle

Gordon, B. ; Lyden, E. ; Lynch, J. ; Tarantolo, S. ; Pavletic, Z. S. ; Bishop, M. ; Reed, E. ; Kessinger, A. ; Haire, W. / Central nervous system dysfunction as the first manifestation of multiple organ dysfunction syndrome in stem cell transplant patients. In: Bone marrow transplantation. 2000 ; Vol. 25, No. 1. pp. 79-83.
@article{a2b2e7d350b74a3eab51cb53f6832e95,
title = "Central nervous system dysfunction as the first manifestation of multiple organ dysfunction syndrome in stem cell transplant patients",
abstract = "Development of CNS dysfunction in the setting of hematopoietic stem cell transplant (HSCT) has been previously shown to predict for subsequent second organ dysfunction and death. In this paper, we describe the characteristics of this isolated CNS dysfunction, and its relationship to multiple organ dysfunction syndrome (MODS) after HSCT. Twenty-one of 186 patients undergoing HSCT developed CNS dysfunction as their first organ dysfunction a mean of 22.8 ± 0.9 days after the start of the preparative regimen. Compared with 137 patients who developed no organ dysfunction, patients presenting with CNS dysfunction were more likely to have undergone allogeneic HSCT (P = 0.001) and to have received a total body irradiation-based regimen (P = 0.001), and were less likely to have been transplanted for lymphoma (P = 0.008). Patients who developed CNS dysfunction were more likely to die than those with no organ dysfunction (P < 0.001). Of the 21 patients who developed CNS dysfunction, 48{\%} resolved their dysfunction by a mean of 4.6 days later without progression to second organ dysfunction, and 90{\%} of these patients survived to day 100. Fifty-two percent of patients with CNS dysfunction progressed to second organ dysfunction (pulmonary or hepatic) a mean of 5.5 days later, and only 36{\%} survived to day 100 (P = 0.02). The patients who progressed to second organ dysfunction and those who did not were not different in terms of type of HSCT (allogeneic vs autologous), stem cell source (blood vs bone marrow), age, diagnosis or preparative regimen. Development of CNS dysfunction in the setting of HSCT, as with other organ dysfunctions (such as hepatic veno-occlusive disease), probably represents an early manifestation of a systemic disorder predisposing for MODS, increasing the risk of transplant-related mortality. Early systemic therapies directed at modulating this systemic disorder are probably indicated.",
keywords = "CNS dysfunction, Multiple organ dysfunction, Stem cell transplant",
author = "B. Gordon and E. Lyden and J. Lynch and S. Tarantolo and Pavletic, {Z. S.} and M. Bishop and E. Reed and A. Kessinger and W. Haire",
year = "2000",
month = "1",
day = "1",
doi = "10.1038/sj.bmt.1702082",
language = "English (US)",
volume = "25",
pages = "79--83",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Central nervous system dysfunction as the first manifestation of multiple organ dysfunction syndrome in stem cell transplant patients

AU - Gordon, B.

AU - Lyden, E.

AU - Lynch, J.

AU - Tarantolo, S.

AU - Pavletic, Z. S.

AU - Bishop, M.

AU - Reed, E.

AU - Kessinger, A.

AU - Haire, W.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Development of CNS dysfunction in the setting of hematopoietic stem cell transplant (HSCT) has been previously shown to predict for subsequent second organ dysfunction and death. In this paper, we describe the characteristics of this isolated CNS dysfunction, and its relationship to multiple organ dysfunction syndrome (MODS) after HSCT. Twenty-one of 186 patients undergoing HSCT developed CNS dysfunction as their first organ dysfunction a mean of 22.8 ± 0.9 days after the start of the preparative regimen. Compared with 137 patients who developed no organ dysfunction, patients presenting with CNS dysfunction were more likely to have undergone allogeneic HSCT (P = 0.001) and to have received a total body irradiation-based regimen (P = 0.001), and were less likely to have been transplanted for lymphoma (P = 0.008). Patients who developed CNS dysfunction were more likely to die than those with no organ dysfunction (P < 0.001). Of the 21 patients who developed CNS dysfunction, 48% resolved their dysfunction by a mean of 4.6 days later without progression to second organ dysfunction, and 90% of these patients survived to day 100. Fifty-two percent of patients with CNS dysfunction progressed to second organ dysfunction (pulmonary or hepatic) a mean of 5.5 days later, and only 36% survived to day 100 (P = 0.02). The patients who progressed to second organ dysfunction and those who did not were not different in terms of type of HSCT (allogeneic vs autologous), stem cell source (blood vs bone marrow), age, diagnosis or preparative regimen. Development of CNS dysfunction in the setting of HSCT, as with other organ dysfunctions (such as hepatic veno-occlusive disease), probably represents an early manifestation of a systemic disorder predisposing for MODS, increasing the risk of transplant-related mortality. Early systemic therapies directed at modulating this systemic disorder are probably indicated.

AB - Development of CNS dysfunction in the setting of hematopoietic stem cell transplant (HSCT) has been previously shown to predict for subsequent second organ dysfunction and death. In this paper, we describe the characteristics of this isolated CNS dysfunction, and its relationship to multiple organ dysfunction syndrome (MODS) after HSCT. Twenty-one of 186 patients undergoing HSCT developed CNS dysfunction as their first organ dysfunction a mean of 22.8 ± 0.9 days after the start of the preparative regimen. Compared with 137 patients who developed no organ dysfunction, patients presenting with CNS dysfunction were more likely to have undergone allogeneic HSCT (P = 0.001) and to have received a total body irradiation-based regimen (P = 0.001), and were less likely to have been transplanted for lymphoma (P = 0.008). Patients who developed CNS dysfunction were more likely to die than those with no organ dysfunction (P < 0.001). Of the 21 patients who developed CNS dysfunction, 48% resolved their dysfunction by a mean of 4.6 days later without progression to second organ dysfunction, and 90% of these patients survived to day 100. Fifty-two percent of patients with CNS dysfunction progressed to second organ dysfunction (pulmonary or hepatic) a mean of 5.5 days later, and only 36% survived to day 100 (P = 0.02). The patients who progressed to second organ dysfunction and those who did not were not different in terms of type of HSCT (allogeneic vs autologous), stem cell source (blood vs bone marrow), age, diagnosis or preparative regimen. Development of CNS dysfunction in the setting of HSCT, as with other organ dysfunctions (such as hepatic veno-occlusive disease), probably represents an early manifestation of a systemic disorder predisposing for MODS, increasing the risk of transplant-related mortality. Early systemic therapies directed at modulating this systemic disorder are probably indicated.

KW - CNS dysfunction

KW - Multiple organ dysfunction

KW - Stem cell transplant

UR - http://www.scopus.com/inward/record.url?scp=0033951663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033951663&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1702082

DO - 10.1038/sj.bmt.1702082

M3 - Article

C2 - 10654019

AN - SCOPUS:0033951663

VL - 25

SP - 79

EP - 83

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -